Overview

SPD503 (Guanfacine Hydrochloride) in ADHD Plus Oppositional Symptoms

Status:
Completed
Trial end date:
2008-01-04
Target enrollment:
Participant gender:
Summary
To assess efficacy and safety of SPD503(guanfacine hydrochloride) in subjects with ADHD and oppositional symptoms.
Phase:
Phase 3
Details
Lead Sponsor:
Shire
Treatments:
Guanfacine